Septerna (SEPN) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Septerna (SEPN) has outperformed Trevi Therapeutics (TRVI) over the past year, gaining 64.1% versus a gain of 30.6%. Trevi Therapeutics is the larger company by market cap ($1.88 billion vs $1.79 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SEPN | TRVI |
|---|---|---|
| Share price | $38.37 | $13.19 |
| Market cap | $1.79B | $1.88B |
| 1-day change | +3.98% | +2.85% |
| YTD return | +32.35% | +2.44% |
| 1-year return | +64.07% | +30.60% |
| 5-year return | — | +894.19% |
| EPS (TTM) | $-0.54 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $45.95M | — |
| Revenue growth (YoY) | +4174.51% | — |
| Net income (latest FY) | $-48.88M | $-42.76M |
| Operating margin | -148.63% | — |
| Net margin | -106.37% | — |
| 52-week high | $51.10 | $20.22 |
| 52-week low | $17.55 | $9.28 |
| Distance from 52-week high | -24.91% | -34.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +41.31% | +113.65% |
| Average volume | 390.47K | 2.03M |
| Shares outstanding | 46.68M | 142.48M |
| Employees | 123 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed TRVI by 33.5 percentage points over the past year.
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
SEPN vs TRVI FAQ
Which is bigger, Septerna or Trevi Therapeutics?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.88B compared with $1.79B for Septerna (SEPN).
Which stock has performed better over the past year, SEPN or TRVI?
SEPN returned +64.07% over the past 12 months, compared with +30.60% for TRVI (price return, excluding dividends). Past performance does not predict future results.
Are Septerna and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.